Spalletta Gianfranco

31/05/2016 Off By IMS Tor Vergata

Go to top

Subject: Psychiatry

Go to top

email: g.spalletta@hsantalucia.it

office: 0620903131

Go to top

Curriculum:

CURRICULUM VITAE

Gianfranco Spalletta, MD, PhD

 

 

Home Address:                                                                     Work Office Address:

via Accademia Albertina, 12                                                IRCCS Santa Lucia Foundation

00147 Rome, Italy                                                                Via Ardeatina, 306

tel. 0039-339-4659753                                                         00179 Rome, Italy

e-mail: gianfraspall@tin.it                                                   tel. 0039-06-51501575

                                                                                              fax 0039-06-51501575

                                                                                              e-mail: g.spalletta@hsantalucia.it

                                                                                              internet: www.hsantalucia.it

 

Education:

1991                M.D. in Medicine and Surgery, La Sapienza University of Rome, Summa cum laude.

1991 -1995     Resident in psychiatry, Tor Vergata University of Rome, Summa cum laude.

1992 –             Medical licence, Ordine dei Medici di Roma, n. 43807, from March 30, 1992

2004 – 2007    Ph.D. in Neuropsychology, Catholic University of the Sacred Heart of Rome.

Professional experience (research):

2000 –             Head of the Neuropsychiatry Laboratory, Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation.

2001 –  2004   Research Psychiatrist, Department of Neuroscience, University of Rome Tor Vergata.

Professional experience (clinical):

1991 – 1995    Clinical Assistant in Psychiatry, University of Rome Tor Vergata.

1996 – 2000    Clinical Assistant in Psychiatry, Neuropsychiatry Department, Military Hospital of Rome.

1998 – 1999    Clinical Director, Therapeutic Community “Residenza Morgagni” in Rome.

2001 –              Psychiatric Lyason Service, IRCCS Santa Lucia Foundation, Rome.

2005 –                 Clinical Director, Neuropsychiatric Outpatient Clinic, IRCCS Santa Lucia Foundation, Rome.

2006 –             Clinical Neuropsychology Consultant, Neurogeriatric Center, Tor Vergata Hospital, University of Rome Tor Vergata.

2010 –                 Clinical Director, Memory Clinic, IRCCS Santa Lucia Foundation, Rome.

Professional experience (didactic):

1996 – 1999    Adjunct Professor of Psychopharmacology, School of Specialization in Psychiatry, Faculty of Medicine, University of Rome Tor Vergata.

1994 –  2001   Adjunct Professor of Psychiatry. Faculty of Medicine. University of Rome Tor Vergata.

2001 –             Adjunct Professor of Psychiatry, School for Nurses, University of Rome Tor Vergata.

2003 –             Adjunct Professor of Psychiatry, School of  Speech Therapy, University of Rome Tor Vergata.

2005 – 2009    College of Professors of the PhD course “Advanced Research and Methodologies in Psychoterapy and Psychopathology”, Catholic University of the Sacred Heart of Rome.

2011 –             Adjunct Professor of Translational Psychiatry and Research Methodology, School of  Specialization in Psychiatry, Faculty of Medicine, Sapienza University of Rome.

2013                Visiting Professor, Iowa University, Carver College of Medicine, Department of Psychiatry, Iowa City, USA.

2014                Visiting Professor, Baylor College of Medicine, Menninger Department of Psychiatry and Behavioral Sciences, Houston, TX, USA.

2015 –             Adjunct Associate Professor, Baylor College of Medicine, Menninger Department of Psychiatry and Behavioral Sciences, Beth K. and Stuart C. Yudofsky Division of Neuropsychiatry, Houston, TX, USA

Professional experience (foreign countries):

1996                Department of Psychiatry, Timeside General Hospital, Manchester, UK.

1997                Neuroimaging centre, Great Ormond Street Hospital, London, UK.

  • Therapeutic Community, Winterbourne, Reading, Berkshire, UK.

1999                Psychiatric Institute of Washington, USA.

2005                Maryland Psychiatric Research Center, Baltimore, USA.

2005                Western Psychiatric Research Institute, Pittsburgh, USA

2013                Iowa University, Carver College of Medicine, Department of Psychiatry, Iowa City, USA.

2014                Baylor College of Medicine, Department of Psychiatry, Houston, TX, USA.

Societies:

1993 –                Italian Society of Biological Psychiatry (SIPB)

1994 –                Italian Psychiatric Society (SIP)

1997 – 2007     New York Academy of Sciences (New York – USA)

1998 – 2002    Association of Therapeutic Communities (London – UK)

2003 –             Italian Psychogeriatric Association (AIP)

2004 –                Italian Neurological Society for Dementia (SINDEM)

Editorial Review Board

2001 –             The Journal of Applied Research, in Clinical and Experimental Therapeutics

2007 –             The Open Longevity Science

2010 –             Journal of Alzheimer’s Disease

2010 –             International Journal of Clinical and Experimental Medicine

2012 –             World Journal of Neurology

2012 –             World Journal of Psychiatry

2012 –             World Journal of Methodology

2013 –             Advances in Medicine

2014 –             Behavioural Neurology

2014 –             Neuroimmunology and Neuroinflammation (Associate Editor)

2014 –             Annals of Depression and Anxiety

2014 –             Austin Alzheimer’s and Parkinson’s Disease

Ad Hoc Manuscript Referee:

Acta Neurologica Scandinavica, Acta Psychiatrica Scandinavica, Aging Cell, Aging Health, Alzheimer Disease & Associated Disorders, American Journal of Geriatric Psychiatry, Annals of Neurology, Archives of General Psychiatry, Archives of Suicide Research, Biological Psychiatry, BMC Psychiatry, Brain, Brain and Cognition, Cerebral Cortex, Cochrane Reviews; Comprehensive Psychiatry, Cortex, Current Alzheimer Research, European Neuropsychopharmacology, European Psychiatry, Expert Opinion in Pharmacotherapy, General Hospital Psychiatry, Genes Brain and Behavior, Human Brain Mapping, International Journal of Clinical Practice, International Journal of Psychiatry in Medicine, Journal of Clinical Psychiatry, Journal of Geriatric Psychiatry and Neurology, Journal of Neural Transmission, Journal of Neuroinflammation, Journal of the Neurological Sciences, Journal of Neurology, Journal of Neurology Neurosurgery and Psychiatry, Journal of Neuropsychiatry and Clinical Neurosciences, The Journal of Neuroscience, Journal of Psychiatry and Neuroscience, Journal of Psychiatric Research, Journal of Psychosomatic Research, Medical Science Monitor, Metallomics, Nature Reviews Neurology, Neurological Sciences, Neurology, Neuropsychiatry, Neuropsychobiology, Neuropsychologia, Neuropsychological Rehabilitation, Neuroscience, Neuroscience and Biobehavioral Reviews, Neuroscience Letters, Nordic Journal of Psychiatry, Parkinson’s Disease, PLOS One, Prymary Care Companion, Progress in Neuro-Psychopharmacology & Biological Psychiatry, Psychiatry Research, Psychiatry Research Neuroimaging, Psychological Medicine, Psychoneuroendocrinology, Psycho-Oncology, Psychosomatics, Rejuvenation Research, Schizophrenia Bulletin, Schizophrenia Research, Stroke, Trials

International Societies Grant Referee:

Network of European Funding for Neuroscience Research (NEURON) by the European Commission

Fondation pour la Recherche sur la Maladie Alzheimer (FRMA), Belgium

Danish Council for Independent Research-Medical Sciences, Denmark

Ontario Mental Health Foundation, Canada

Health and Medical Research Fund (HMRF), Hong Kong

Stroke Association, United Kingdom

Medical Research Council (MRC), United Kingdom

Israel Science Foundation, Israel

French National Research Agency (ANR)

Research Grant (Principal Investigator or Study Coordinator):

2005 – 2007    Italian Ministry of Health (Principal Investigator) PS041S: Neuropathogenetic mechanisms of neurodegenerative disorders: inflammatory and immune process analysis for the identification of new therapeutic targets.

2005 – 2007    Italian Ministry of Health (Principal Investigator) PS04S: Behavioral and psychological symptoms of dementia: a translational approach on the role of pharmacogenetics, immunology and endophenotipic caracterization as precocious predictors of psychopharmacological treatment response.

2005 – 2007    Italian Ministry of Health (National network Principal Investigator) RF04: The national project on neurodegenerative illnesses: a translational project from pathogenesis to therapeutic perspectives.

2006 – 2008    Italian Ministry of Health (Principal Investigator) REG12: Diagnostic and prognostic markers of Alzheimer disease.

2006 – 2008    Italian Ministry of Health (Principal Investigator) RF05.106S: Diagnostic markers for neurodegenerative illnesses and new targets for pharmacological treatment response.

2007 – 2009    Italian Ministry of Health (Principal Investigator) ISS.14: Obtaining optimal functional

recovery and efficient managed care for chronic stroke population.

2007 – 2009    Italian Ministry of Health (Principal Investigator) PS05.l7: A multidisciplinary study on Mild Cognitive Impairment (MCI): neuropsychological, neurophysiological, neuroimaging and biological markers valid for early diagnosis and predictors of dementia conversion.

2007 – 2009    Italian Ministry of Health (Principal Investigator) PS05.5S: Early diagnosis of Lewy Body Dementia using neuroimaging markers.

2008 – 2009    Italian Ministry of Health (Principal Investigator) ISS.l6: Early diagnosis of Alzheimer’s

diseases through the combination of molecular, functional and clinical biomarkers.

2008 – 2010    Italian Ministry of Health (Principal Investigator) RF06.71.1X: Analysis of medical procedures on patients with neurodegenerative within the National Health Service. A comparison between national and international guidelines.

2008 – 2010    Italian Ministry of Health (Principal Investigator) RF06.71.8: Dementia diagnostic procedures for early differential diagnosis valid for the evaluation of rapid and slow progression forms and optimal therapeutic response.

2009 – 2011    Italian Ministry of Health (Principal Investigator)  RF07.96S: Depressive features in medical (neurological and oncological) patients recruited in the general medical setting: reliability of diagnostic criteria, predictive role of biological markers, and effect of treatment with antidepressants.

2009 – 2011    Italian Ministry of Health (Principal Investigator) RF07.39.3X: Cognitive and behavioural indicators of conversion from Mild Cognitive Impairment to neurodegenerative dementias and development of cognitive rehabilitation protocols.

2009 – 2011    Italian Ministry of Health (Principal Investigator) RF07.97.2S: The neuropsychological and neuropsychiatric disturbances in idiopatic Parkinson disease and parkinsonisms: focus on the early diagnosis.

2010 – 2012    Italian Ministry of Health (Principal Investigator) RF08.33X: Behavioral and psychological predictors of cognitive outcome in subjects with Mild Cognitive Impairment: the role of non-conventional and serotonergic genes.

2011 – 2014    European Commission ERA-Net NEURON joint transnational calI 2010. “European

Research Projects on Mental Disorders” (Italian OU Study Coordinator) : NEUCONNECT. Novel strategies for the treatment of schizophrenia based on genetic variation of the neural cell adhesion molecule NCAM and enzymes involved in its posttranslational modifications.

2013-2015   European Commission (Joint Programme – Neurodegenerative Disease Research Transnational research proposals 2013 JPND) Annual Transnational Call (Italian OU Principal Investigator) PERADES008: European research projects for the identification of genetic, epigenetic and environmental risk and protective factors for Neurodegenerative Diseases.

2014-2016      Italian Ministry of Health (Principal Investigator) NET2011-02346784: Development of operational research diagnostic criteria for diagnosis of Alzheimer’s disease in the preclinical/predementia phase and inmplementation of SOPs for imaging and CSF biomarkers in Memory Clinics. An integrated care pathway for early diagnosis.

2015-2018      European Commission (Horizon 2020) (Principal Investigator): PD_MANAGER. Mhealth platform for Parkinson’s disease management.

Invited Speaker (International):

2004                            A dual Congress Psychiatry and Neuroscience. 5th International Congress of Neuropsychiatry. October 14-18, Athens, Greece, 2004. “Post-stroke depression: cognitive impairment, treatment resistance and side of lesion”.

2006                            International College of Geriatric Psychopharmacology. 6th Annual Scientific Meeting,               October, 3-6, Hiroshima, Japan, 2006. “Behavioral syndromes and symptoms in Alzheimer’s disease: are they reactive phenomenon or biologically determined”.

2010                            American Neuropsychiatric Association. 21st Annual Meeting, March 17-20, Tampa, Florida (USA), 2010. “The association of cytokines and inflammatory markers in post-stroke depression”.

2013                            Iowa University Psychiatry Research Seminar. September 16, 2013, Iowa City, USA. “The differential role of apathy and depression on cognitive deterioration progression in mild cognitive impairment and Alzheimer’s disease”.

2013                            Norwegian Neuropsychiatric Association 2013 Annual Meeting. November 27-28, 2013, Oslo, Norway. “Post stroke depression: Clinical outcome, mechanisms and treatment”, “Unawareness as a neuropsychiatric disorder – phenomenology and neural mechanisms”.

Current Research Interests:

  • The role of neuropsychological impairment and neuropsychiatric symptoms as risk factors of dementia conversion in the preclinical/predementia phase of neurodegenerative disorders (Mild Cognitive Impairment, Parkinson disease, Alzheimer disease).
  • The brain neuroanatomy associated to dementia trajectrories.
  • The hippocampal morphometry and memory deficits in Schizophrenia.
  • The brain morphometry of neuropsychological impairment in Bipolar Disorders.
  • The neuroanatomy of neurocognitive deficits in Obsessive Compulsive Disorder.

 

International Bibliography:

Spalletta G, Piras F, Piras F, Sancesario G, Iorio M, Fratangeli C, Cacciari C, Caltagirone C, Orfei MD. Neuroanatomical correlates of awareness of illness in patients with amnestic mild cognitive impairment who will or will not convert to Alzheimer’s disease. Cortex. Submitted.

Spalletta G, Pras F, De Rossi P, Girardi P, Caltagirone C, Kirkpatrick B, Chiapponi C. Brain white matter microstructural maps of deficit and nondeficit subtypes of schizophrenia. Psychiatry Research Neuroimaging. Submitted.

Di Paola M, Phillips O, Orfei MD, Piras F, Cacciari C, Gianni W, Danese E, Caltagirone C, Spalletta G. Corpus callosum structure predicts the early course of cognition and depression in Alzheimer disease. Neurobiology of Aging. Submitted.

Pontieri FE, Assogna F, Pellicano C, Cacciari C, Pannunzi S, Morrone A, Danese E, Caltagirone C, Spalletta G. The neuropsychiatric and cognitive signature of impulse control disorder in Parkinson’s disease without cognitive impairment. European Neuropsychopharmacology. Submitted.

Cutuli D, De Bartolo P, Caporali P, Laricchiuta D, Foti F, Ronci M, Rossi C, Neri C, Spalletta G, Caltagirone C, Farioli-Vecchioli S, Petrosini L. n-3 polyunsaturated fatty acids supplementation restores hippocampal functionality in aged mice. Frontiers in Aging Neuroscience. In Press.

Chiapponi C, Piras F, Fagioli S, Girardi P, Caltagirone C, Spalletta G. Hippocampus age-related microstructural changes in schizophrenia are bilateral, precocious and progressive: a case-control mean diffusivity study. Schizophrenia Research. In Press.

Dahm L, Ott C, Steiner J, Stepniak B, Teegen B, Saschenbrecker S, Hammer C, Borowski K, Begemann M, Lemke S, Rentzsch K, Probst C, Martens H, Wienands J, Spalletta G, Weissenborn K, Stöcker W, Ehrenreich H. Seroprevalence of autoantibodies against brain antigens in health and disease. Annals of Neurology. In Press

Laricchiuta D, Petrosini L, Picerni E, Cutuli D, Chiapponi C, Iorio M, Caltagirone C, Piras F, Spalletta G. The embodied emotion in cerebellum: a neuroimaging study of alexithymia. Brain Structure and Function. In press.

Spalletta G, Robinson RG, Cravello L, Pontieri F, Pierantozzi M, Stefani A, Jeffrey L, Caltagirone C, Assogna F. The early course of affective and cognitive symptoms in de novo patients with Parkinson’s disease. Journal of Neurology. In press

Valentina Escott-Price; Céline Bellenguez; Li-San Wang; Seung-Hoan Choi; Denise Harold; Lesley Jones; Peter Holmans; Amy Gerrish; Alexey Vedernikov; Alexander Richards; Anita L DeStefano; Jean-Charles Lambert; Carla A Ibrahim-Verbaas; Adam C Naj; Rebecca Sims; Gyungah Jun; Joshua C Bis; Gary W Beecham; Benjamin Grenier-Boley; Giancarlo Russo; Tricia A Thornton-Wells; Nicola Jones; Albert V Smith; Vincent Chouraki; Charlene Thomas; M Arfan Ikram; Diana Zelenika; Badri N Vardarajan; Yoichiro Kamatani; Chiao-Feng Lin; Helena Schmidt; Brian Kunkle; Melanie L Dunstan; Maria Vronskaya; Agustin Ruiz; Marie-Thérèse Bihoreau; Christiane Reitz; Florence Pasquier; Paul Hollingworth; Olivier Hanon; Annette Fitzpatrick; Joseph D Buxbaum; Dominique Campion; Paul K Crane; Clinton T Baldwin; Tim Becker; Vilmundur Gudnason; Carlos Cruchaga; David Craig; Najaf Amin; Claudine Berr; Oscar Lopez; Philip L De Jager; Vincent Deramecourt; Janet A Johnston; Denis Evans; Simon Lovestone; Luc Letenneur; Isabel Hernández; David C Rubinsztein; Gudny Eiriksdottir; Kristel Sleegers; Alison M Goate; Nathalie Fiévet; Matthew J Huentelman; Michael Gill; Kristelle Brown; M Ilyas Kamboh; Lina Keller; Pascale Barberger-Gateau; Bernadette McGuinness; Eric B Larson; Amanda J Myers; Carole Dufouil; Stephen Todd; David Wallon; Seth Love; Ekaterina Rogaeva; John Gallacher; Peter St George-Hyslop; Jordi Clarimón; Alberto Lleó; Anthony Bayer; Debby W Tsuang; Lei Yu; Magda Tsolaki; Paola Bossù; Gianfranco Spalletta; Petra Proitsi; John Collinge; Sandro Sorbi; Florentino Sanchez Garcia; Nick Fox; John Hardy; Maria Candida Deniz Naranjo; Paolo Bosco; Robert Clarke; Carol Brayne; Daniela Galimberti; Elio Scarpini; Ubaldo Bonuccelli; Michelangelo Mancuso; Gabriele Siciliano; Susanne Moebus; Patrizia Mecocci; Maria Del Zompo; Wolfgang Maier; Harald Hampel; Alberto Pilotto; Maria Bullido; Francesco Panza; Paolo Caffarra; Benedetta Nacmias; William Perry; Manuel Mayhaus; Lars Lannfelt; Hakon Hakonarson; Sabrina Pichler; Minerva M Carrasquillo; Martin Ingelsson; Duane Beekly; Victoria Alvarez; Fanggeng Zou; Otto Valladares; Steven G Younkin; Eliecer Coto; Kara L Hamilton-Nelson; Wei Gu; Cristina Razquin; Pau Pastor; Ignacio Mateo; Michael J Owen; Kelley M Faber; Palmi V Jonsson; Onofre Combarros; Michael C O’Donovan; Laura B Cantwell; Hilkka Soininen; Deborah Blacker; Simon Mead; Thomas H Mosley Jr; David A Bennett; Tamara B Harris; Laura Fratiglioni; Clive Holmes; Renee FAG de Bruijn; Peter Passmore; Thomas J Montine; Karolien Bettens; Jerome I Rotter; Alexis Brice; Kevin Morgan; Tatiana M Foroud; Walter A Kukull; Didier Hannequin; John Powell; Michael A Nalls; Karen Ritchie; Kathryn L Lunetta; John SK Kauwe; Eric Boerwinkle; Matthias Riemenschneider; Mercè Boada; Mikko Hiltunen; Eden R Martin; Reinhold Schmidt; Dan Rujescu; Jean-François Dartigues; Richard Mayeux; Christophe Tzourio; Albert Hofman; Markus M Nöthen; Caroline Graff; Bruce M Psaty; Jonathan L Haines; Mark Lathrop; Margaret A Pericak-Vance; Lenore J Launer; Christine Van Broeckhoven; Lindsay A Farrer; Cornelia M van Duijn; Alfredo Ramirez; Sudha Seshadri; Gerard D Schellenberg; Philippe Amouyel; Julie Williams. Gene-wide analysis detects two new susceptibility genes for Alzheimer’s disease. Plos ONE. In Press.

Armirotti A, Basit A, Realini N, Caltagirone C, Bossu P, Spalletta G, Piomelli D. Sample Preparation and orthogonal Chromatography for broad polarity range plasma metabolomics. Application to human subjects with neurodegenerative dementia. Analytical Biochemistry. In Press.

Spalletta G, Piras F, Piras F, Caltagirone C, Orfei MD. The structural neuroanatomy of metacognitive insight in schizophrenia and its psychopathological and neuropsychological correlates. Human Brain Mapping. In Press.

Sannino S, Gozzi A, Cerasa A, Piras F, Scheggia D, Manago F, Damiano M, Galbusera A, Erickson LC, De Pietri Tonelli D, Bifone A, Tsaftaris SA, Caltagirone C, Weinberger DR, Spalletta G, Papaleo F. COMT genetic reduction produces sexually-divergent effects on cortical anatomy and working memory in mice and humans. Cerebral Cortex. In Press.

Flex A, Giovannini S, Biscetti F, Liperoti R, Spalletta G, Straface G, Landi F, Angelini F, Caltagirone C, Ghirlanda G, Bernabei R. Effect of Proinflammatory Gene Polymorphisms on the Risk of Alzheimer’s Disease. Neurodegenerative Diseases. In Press.

Hammer C, Stepniak B, Schneider A, Papiol S, Tantra M, Begemann M, Sirén AL, Pardo LA, Sperling S, Mohd Jofrry S, Gurvich A, Jensen N, Ostmeier K, Lühder F, Probst C, Martens H, Gillis M, Saher G, Assogna F, Spalletta G, Stöcker W, Schulz TF, Nave KA, Ehrenreich H. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Molecular Psychiatry. In Press.

Piras F, Piras F, Chiapponi C, Girardi P, Caltagirone C, Spalletta G. Widespread structural brain changes in OCD: A systematic review of voxel-based morphometry studies. Cortex. In Press.

Cerasa A, Quattrone A, Piras F, Mangone G, Magariello A, Fagioli S, Girardi P, Muglia M, Caltagirone C, Spalletta G. 5-HTTLPR, anxiety and gender interaction moderates right amygdala volume in healthy subjects. Social Cognitive and Affective Neuroscience. In Press.

  1. Spalletta G, Piras F, Fagioli S, Caltagirone C, Piras F. Brain microstructural changes and cognitive correlates in patients with pure obsessive compulsive disorder. Brain and Behavior. 2014;4:261-277.
  2. Spalletta G, Caltagirone C, Padovani A, Sorbi S, Attar M, Colombo D, Cravello L, EVOLUTION study Group. Cognitive and affective changes in mild to moderate Alzheimer’s Disease patients undergoing switch of cholinesterase inhibitors. Plos ONE. 2014;9:e89216.
  3. Rose EJ, Hargreaves A, Morris D, Fahey C, Tropea D, Cummings L, Caltagirone C, Bossù P, Chiapponi C, Piras F, Spalletta G, Gill M, Corvin A, Donohoe.G. The novel psychosis risk variant rs7914558 at CNNM2: Effects on social cognition. British Journal of Psychiatry. 2014;204:115-121.
  4. Papiol S, Mitjans M, Assogna F, Piras F, Hammer C, Caltagirone C, Arias B, Ehrenreich H, Spalletta G. Polygenic determinants of white matter volume derived from GWAS lack reproducibility in a replicate sample. Translational Psychiatry. 2014;4:e362.
  5. Piras F, Piras F, Ciullo V, Danese E, Caltagirone C, Spalletta G. Time dysperception perspective for acquired brain injury. Frontiers in Neurology. 2014;4:217.
  6. Laricchiuta D, Petrosini L, Piras F, Cutuli D, Macci E, Picerni E, Chiapponi C, Caltagirone C,Spalletta G. Linking novelty seeking and harm avoidance personality traits to basal ganglia: volumetry and mean diffusivity. Brain Structure and Function. 2014;35:285-296.
  7. Spalletta G, Piras F, Caltagirone C, Fagioli S. Hippocampal multimodal structural changes and subclinical depression in healthy individuals. Journal of Affective Disorders. 2014;152-154:105-112.
  8. Picchetto L, Spalletta G, Casolla B, Cacciari C, Cavallari M, Fantozzi C, Ciuffoli A, Rasura M, Imperiale F, Sette G, Caltagirone C, Taurino M, Orzi F. Cognitive performance following carotid endarterectomy or stenting in asymptomatic patients with severe ICA stenosis. Cardiovascular Psychiatry and Neurology. 2013;2013:342571.
  9. Iorio M, Spalletta G, Chiapponi C, Luccichenti G, Cacciari C, Orfei MD, Caltagirone C, Piras F. White matter hyperintensities segmentation: a new semi-automated method. Frontiers in Aging Neuroscience. 2013;5:76. IF=2.843
  10. Piras F, Piras F, Caltagirone C,Spalletta G. Brain circuitries of obsessive compulsive disorder: A systematic review and meta-analysis of diffusion tensor imaging studies. Neuroscience and Biobehavioral Reviews. 2013;37:2856-2877. IF=10.284
  11. Spalletta G, Cravello L, Imperiale F, Salani F, Bossù P, Picchetto L, Cao M, Rasura M, Pazzelli F, Orzi F, Caltagirone C, Robinson RG, Cacciari C. Neuropsychiatric symptoms and interleukin-6 serum levels in acute stroke. Journal of Neuropsychiatry and Clinical Neuroscience. 2013;25:255-263.IF=2.765
  12. Chiapponi C, Piras F, Piras F, Fagioli S, Caltagirone C,Spalletta G. Cortical grey matter and subcortical white matter brain microstructural changes in schizophrenia are localised and age independent: a case-control diffusion tensor imaging study. PLoS One. 2013;8(10):e75115. IF=3.534
  13. Picerni E, Petrosini L, Piras F, Laricchiuta D, Cutuli D, Chiapponi C, Fagioli S, Girardi P, Caltagirone C,Spalletta G. New evidence for the cerebellar involvement in personality traits. Frontiers in Behavioral Neuroscience. 2013;7:133.IF=4.160
  14. Fanciulli A, Assogna F, Caltagirone C,Spalletta G, Pontieri FE. Rotigotine for anxiety during wearing-off in Parkinson’s disease with dementia. Aging Clinical and Experimental Research. 2013;25:601-603. IF=1.138
  15. Mariani S, Ventriglia M, Simonelli I,Spalletta G, Bucossi S, Siotto M, Assogna F, Melgari JM, Vernieri F, Squitti R. Effects of hemochromatosis and transferrin gene mutations on peripheral iron dyshomeostasis in mild cognitive impairment and Alzheimer’s and Parkinson’s diseases. Frontiers in Aging Neuroscience. 2013;5:37. IF=2.843
  16. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, Jun G, Destefano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thornton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH, Reitz C, Pasquier F, Hollingworth P, Ramirez A, Hanon O, Fitzpatrick AL, Buxbaum JD, Campion D, Crane PK, Baldwin C, Becker T, Gudnason V, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Morón FJ, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fiévet N, Huentelman MJ, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuinness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossù P,Spalletta G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC, Hardy J, Naranjo MC, Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, Matthews F; European Alzheimer’s Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer’s Disease (GERAD); Alzheimer’s Disease Genetic Consortium (ADGC); Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE), Moebus S, Mecocci P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M, Lannfelt L, Hakonarson H, Pichler S, Carrasquillo MM, Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razquin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O, O’Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley TH Jr, Bennett DA, Harris TB, Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, Montine TJ, Bettens K, Rotter JI, Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider M, Boada M, Hiltunen M, Martin ER, Schmidt R, Rujescu D, Wang LS, Dartigues JF, Mayeux R, Tzourio C, Hofman A, Nöthen MM, Graff C, Psaty BM, Jones L, Haines JL, Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ, Farrer LA, van Duijn CM, Van Broeckhoven C, Moskvina V, Seshadri S, Williams J, Schellenberg GD, Amouyel P. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nature Genetics. 2013;45:1452-1458. IF=29.648
  17. Ciaramella A, Salani F, Bizzoni F, Pontieri FE, Stefani A, Pierantozzi M, Assogna F, Caltagirone C, Spalletta G, Bossù P. Blood Dendritic Cell Frequency Declines in Idiopathic Parkinson’s Disease and Is Associated with Motor Symptom Severity. PLoS ONE. 2013; 8(6): e65352. IF=3.534
  18. Chiapponi C, Piras F, Piras F, Fagioli S, Caltagirone C, Spalletta G. Age-related brain trajectories in schizophrenia: a systematic review of structural MRI studies. Psychiatry Research Neuroimaging. 2013;214:83-93. IF=2.831
  19. Sancesario G, Esposito Z, Mozzi AF, Sancesario GM, Martorana A, Giordano A, Sorge R, Mari B, Spalletta G, Marciani MG, Bernardini S. Transient global amnesia: Linked to a systemic disorder of amino acid catabolism? Journal of Neurology. 2013;260-1429-1432. IF=3.841
  20. Iuliano L, Pacelli L, Ciacciarelli M, Zerbinati C, Fagioli S, Piras F, Orfei MD, Caltagirone C, Spalletta G. Plasma Fatty Acids Lipidomics in Amnestic Mild Cognitive Impairment and Alzheimer’s Disease. Journal of Alzheimer Disease, 2013;36:545-553. IF=3.612
  21. Ciaramella A. Salani F, Bizzoni F, Angelucci F, Spalletta G, Taddei AR, Caltagirone C Bossù P. The stimulation of dendritic cells by amyloid beta 1-42 reduces BDNF production in Alzheimer’s disease patients. Brain, Behavior and Immunity. 2013;32:29-32. IF=6.128
  22. Spalletta G, De Luca V, Padovani A, Rozzini L, Perri R, Bruni A, Canonico V, Trequattrini A, Bellelli G, Pettenati C, Caltagirone C, Orfei MD. Early onset versus late onset in Alzheimer’s disease: what is the reliable cut-off? Advances in Alzheimer Disease. 2013;2:40-47.
  23. Porto I, Della Bona R, Leo A, Proietti R, Pieroni M, Caltagirone C, Spalletta G, Bolognese L, Cravello L. Stress cardiomyopathy (Tako-Tsubo) triggered by nervous system diseases: a systematic review of the reported cases. International Journal of Cardiology. 2013;167:2441-2448. IF=6.175
  24. Di Paola M, Luders E, Rubino IA, Siracusano A, Manfredi G, Girardi P, Martinotti G, Thompson PM, Chou YY, Toga AW, Caltagirone C, Spalletta G. The structure of the corpus callosum in obsessive compulsive disorder. European Psychiatry. 2013; 28:499-506. IF=3.210
  25. Spalletta G, Fagioli S, Caltagirone C, Piras F. Brain microstructure of subclinical apathy phenomenology in healthy individuals. Human Brain Mapping. 2013;34:3193-3203. IF=6.924
  26. Spalletta G, Gianni W, Giubilei F, Casini AR, Sancesario G, Caltagirone C, Cravello L. Rivastigmine patch ameliorates depression in mild AD: preliminary evidence from a six-month observational study. Alzheimer Disease and Associated Disorders. 2013;27:289-291. IF=2.688
  27. Assogna F, Fagioli S, Cravello L, Meco G, Pierantozzi M, Stefani A, Imperiale F, Caltagirone C, Pontieri FE, Spalletta G. Depressive symptoms in Parkinson’s disease and in non-neurological medical illnesses. Neuropsychiatric Disease and Treatment. 2013;9:389-396. IF=2.154
  28. Spalletta G, Piras F, Rubino IA, Caltagirone C, Fagioli S. Fronto-thalamic volumetry markers of somatic delusions and hallucinations in schizophrenia. Psychiatry Research Neuroimaging. 2013;212:54-64. IF=2.831
  29. Spalletta G, Fagioli S, Meco G, Pierantozzi M, Stefani A, Pisani V, Caltagirone C, Pontieri FE, Assogna F. Hedonic tone and its mood and cognitive correlates in Parkinson’s disease. Depression and Anxiety. 2013;30:85-91. IF=4.288
  30. Salani F, Ciaramella A, Bizzoni F, Assogna F, Caltagirone C, Spalletta G, Bossù P. Increased expression of Interleukin-18 receptor in blood cells of subjects with Mild Cognitive Impairment and Alzheimer’s disease. Journal of Neuroinflammation. Cytokine. 2013;61:260-263. IF=4.902
  31. Spalletta G, Piras F, Rubino IA, Caltagirone C, Fagioli S. Fronto-thalamic volumetry markers of somatic delusions and hallucinations in schizophrenia. Psychiatry Research Neuroimaging. 2013;212:54-64. IF=2.831
  32. Fanciulli A, Strano S, Colosimo C, Caltagirone C, Spalletta G, Pontieri FE. The potential prognostic role of cardiovascular autonomic failure in a-synucleinopathies. European Journal of Neurology. 2013;20:231-235. IF=3.852
  33. Spalletta G, Cravello L, Piras F, Iorio M, Sancesario G, Marchi A, Caltagirone C, Cacciari C. Rapid-onset apathy may be the only clinical manifestation after dorsal striatum hemorrhagic lesion: a case report. Alzheimer Disease and Associated Disorders. 2013;27:192-194. IF=2.688
  34. Lambert JC, Grenier-Boley B, Harold D, Zelenika D, Chouraki V, Kamatani Y, Sleegers K, Ikram MA, Hiltunen M, Reitz C, Mateo I, Feulner T, Bullido M, Galimberti D, Concari L, Alvarez V, Sims R, Gerrish A, Chapman J, Deniz-Naranjo C, Solfrizzi V, Sorbi S, Arosio B, Spalletta G, Siciliano G, Epelbaum J, Hannequin D, Dartigues JF, Tzourio C, Berr C, Schrijvers EM, Rogers R, Tosto G, Pasquier F, Bettens K, Van Cauwenberghe C, Fratiglioni L, Graff C, Delepine M, Ferri R, Reynolds CA, Lannfelt L, Ingelsson M, Prince JA, Chillotti C, Pilotto A, Seripa D, Boland A, Mancuso M, Bossù P, Annoni G, Nacmias B, Bosco P, Panza F, Sanchez-Garcia F, Del Zompo M, Coto E, Owen M, O’Donovan M, Valdivieso F, Caffara P, Scarpini E, Combarros O, Buée L, Campion D, Soininen H, Breteler M, Riemenschneider M, Van Broeckhoven C, Alpérovitch A, Lathrop M, Trégouët DA, Williams J, Amouyel P. Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer’s disease. Mol Psychiatry. 2013;18:461-470. IF=15.147
  35. Orfei MD, Piras F, Macci E, Caltagirone C, Spalletta G. The neuroanatomical correlates of cognitive insight in schizophrenia. Social Cognitive and Affective Neuroscience. 2013;8:418-423. IF=5.884
  36. Spalletta G, Assogna F, Caltagirone C. Alexithymia in Parkinson’s disease: secondary phenomenon or primary neuropsychiatric feature? Neurodegenerative Disease Management. 2012;2:343-346.
  37. Spalletta G, Piras F, Gravina P, Bernardini S, Caltagirone C. Glutathione S-Transferase Alpha 1 risk polymorphism and increased bilateral thalamus mean diffusivity in schizophrenia. Psychiatry Research Neuroimaging. 2012;203:180-183. IF=3.364
  38. Palladino I, Salani F, Ciaramella A, Rubino IA, Caltagirone C, Fagioli S, Spalletta G, Bossù P. Elevated levels of circulating IL-18 and perturbed regulation of IL-18 in schizophrenia. Journal of Neuroinflammation. 2012;9:206. IF=4.351
  39. Sancesario GM, Cencioni MT, Esposito Z, Borsellino G, Nuccetelli M, Martorana A, Battistini L, Sorge R, Spalletta G, Ferrazzoli D, Bernardi G, Bernardini S, Sancesario G. The Load of Amyloid-β Oligomers is Decreased in the Cerebrospinal Fluid of Alzheimer’s Disease Patients. J Alzheimers Dis. 2012;31:865-878. IF=4.174
  40. Pontieri FE, Assogna F, Stefani A, Pierantozzi M, Meco G, Benincasa D, Colosimo C, Caltagirone C, Spalletta G. Sad and happy facial emotion recognition impairment in progressive supranuclear palsy in comparison with Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:871-875. IF=3.274
  41. Spalletta G, Caltagirone C, Girardi P, Gianni W, Casini AR, Palmer K. The role of persistent and incident major depression on rate of cognitive deterioration in newly diagnosed Alzheimer’s disease patients. Psychiatry Research. 2012;198:263-268. IF=2.456
  42. Carlesimo GA, Piras F, Assogna F, Pontieri FE, Caltagirone C, Spalletta G. Hippocampal abnormalities and memory deficits in Parkinson disease: A multimodal imaging study. Neurology. 2012;78:1939-1945. IF=8.249
  43. Piras F, Salani F, Bossù P, Caltagirone C, Spalletta G. High serum levels of Transforming Growth Factor Beta 1 are associated with increased cortical thickness in cingulate and right frontal areas in healthy subjects. Journal of Neuroinflammation. 2012;9:42. IF=4.351
  44. Spalletta G, Girardi P, Caltagirone C, Orfei MD.. Anosognosia and Neuropsychiatric Symptoms and Disorders in Mild AD and Mild Cognitive Impairment. Journal of Alzheimer’s Disease. 2012;29:761-772. IF=4.174
  45. Assogna F, Palmer K, Pontieri FE, Pierantozzi M, Stefani A, Gianni W, Caltagirone C, Spalletta G. Alexithymia is a non-motor symptom of Parkinson’s disease. American Journal of Geriatric Psychiatry. 2012;20:133-141. IF=4.295
  46. Pellicano C, Assogna F, Piras F, Caltagirone C, Pontieri FE, Spalletta G. Regional Cortical Thickness and Cognitive Functions in Non-demented Parkinson’s Disease Patients: a Pilot Study. European Journal of Neurology. 2012;19:172-175. IF=4.162
  47. Ascolani A, Balestrieri E, Minutolo A, Mosti S, Spalletta G, Bramanti P, Mastino A, Caltagirone C, Macchi B. Dysregulated NF-κB Pathway in Peripheral Mononuclear Cells of Alzheimer’s Disease Patients. Current Alzheimer Research. 2012;9:128-137. IF=3.676
  48. Adriano F, Caltagirone C, Spalletta G. Hippocampus volume reduction in first-episode and chronic schizophrenia: A review and meta-analysis study. The Neuroscientist. 2012;18:180-200. IF=5.633
  49. Orfei MD, Caltagirone C, Cacciari C, Assogna F, Spalletta G. The neuropsychological correlates of cognitive insight in healthy subjects. Applied Cognitive Psychology. 2011;25:927-932. IF=1.667
  50. Di Paola M, Caltagirone C, Spalletta G. What does the corpus callosum tell us about brain changes in the elderly? Expert Review of Neurotherapeutics. 2011;11:1557-1560. IF=2.955
  51. Assogna F, Cravello L, Caltagirone C, Spalletta G. Anhedonia in Parkinson’s Disease: a systematic review of the literature. Movement Disorders. 2011;26:1825-1834. IF=4.505
  52. Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, Bullido MJ, Engelborghs S, De Deyn P, Berr C, Pasquier F, Dubois B, Tognoni G, Fiévet N, Brouwers N, Bettens K, Arosio B, Coto E, Del Zompo M, Mateo I, Epelbaum J, Frank-Garcia A, Helisalmi S, Porcellini E, Pilotto A, Forti P, Ferri R, Scarpini E, Siciliano G, Solfrizzi V, Sorbi S, Spalletta G, Valdivieso F, Vepsäläinen S, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossù P, Hanon O, Piccardi P, Annoni G, Seripa D, Galimberti D, Licastro F, Soininen H, Dartigues J-F, Kamboh MI, Van Broeckhoven C, Lambert JC, Amouyel P, Campion D. APOE and Alzheimer Disease: a major gene with semi-dominant inheritance. Molecular Psychiatry. 2011;16:903-907. IF=13.668
  53. De Gennaro L, Cipolli C, Cherubini A, Assogna F, Cacciari C, Marzano C, Curcio G, Ferrara M, Caltagirone C, Spalletta G. Amigdala and hippocampus volumetry and diffusivity in relation to dreaming. Human Brain Mapping. 2011;32:1458-1470. IF=5.880
  54. Lambert JC, Zelenika D, Hiltunen M, Chouraki V, Combarros O, Bullido MJ, Tognoni G, Fiévet N, Boland A, Arosio B, Coto E, Zompo MD, Mateo I, Frank-Garcia A, Helisalmi S, Porcellini E, Pilotto A, Forti P, Ferri R, Delepine M, Scarpini E, Siciliano G, Solfrizzi V, Sorbi S, Spalletta G, Ravaglia G, Valdivieso F, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossù P, Piccardi P, Annoni G, Seripa D, Galimberti D, Licastro F, Lathrop M, Soininen H, Amouyel P.Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. Neurobiology of Aging. 2011;32:756.e11-15. IF=6.189
  55. Ciaramella A, Spalletta G, Bizzoni F, Salani F, Caltagirone C, Bossù P. Effects of age on surface molecules and cytokine expression in human dendritic cells. Cellular Immunology. 2011;269:82-89. IF=1.974
  56. BossùP,SalaniF, AlbericiA, ArchettiS, BellelliG, GalimbertiD, ScarpiniE, Spalletta G, Caltagirone C, Padovani A, Borroni B. Loss of function mutations in the Progranulin gene are related to pro-inflammatory cytokine dysregulation in Frontotemporal Lobar Degeneration patients. Journal of Neuroinflammation. 2011;8:65. IF=3.827
  57. Spoletini I, Gianni W, Caltagirone C, Madaio R, Repetto L, Spalletta G. Suicide and cancer: where do we go from here? Critical Reviews in Oncology/Hematology. 2011;78:206-219. IF=4.411
  58. Cerasa A, Quattrone A, Gioia MC, Magariello A, Muglia M, Assogna F, Bernardini S, Caltagirone C, Bossù P, Spalletta G. MAO A VNTR polymorphism and amygdala volume in healthy subjects. Psychiatry Research Neuroimaging. 2011;191:87-91. IF=2.964
  59. Gravina P, Spoletini I, Masini S, Valentini A, Vanni D, Paladini E, Bossù P, Caltagirone C, Federici G, Spalletta G, Bernardini S. Genetic polymorphisms of glutathione S-transferases GSTM1, GSTT1, GSTP1 and GSTA1 as risk factors for schizophrenia. Psychiatry Research. 2011;187:454-456. IF=2.524
  60. Cravello L, Palmer K, de Girolamo G, Caltagirone C, Spalletta G. Neuropsychiatric symptoms and syndromes in istituzionalized elderly people without dementia. International Psychogeriatrics. 2011;23:425-434. IF=2.240
  61. Cerasa A, Quattrone A, Gioia MC, Tarantino P, Annesi G, Assogna F, Caltagirone C, De Luca V, Spalletta G. Dysbindin C-A-T haplotype is associated with thicker medial orbitofrontal cortex in healthy population. Neuroimage. 2011;55:508-513. IF=5.895
  62. Cerasa A, Quattrone A, Gioia MC, Magariello A, Muglia M, Assogna F, Bernardini S, Caltagirone C, Bossù P, Spalletta G. MAO A VNTR polymorphism and amygdala volume in healthy subjects. Psychiatry Research Neuroimaging. 2011;191:87-91. IF=2.964
  63. Spoletini I, Cherubini A, Banfi G, Rubino IA, Peran P, Caltagirone C, Spalletta G. Hippocampi, Thalami and Accumbens Microstructural Damage in Schizophrenia: A Volumetry, Diffusivity, and Neuropsychological Study. Schizophrenia Bulletin. 2011;37:118-130. IF=8.800
  64. Angelucci F, Croce N, Spalletta G, Di Nallo V, Gravina P, Bossu P, Federici G, Caltagirone C, Bernardini S. Paroxetine rapidly modulates the expression of brain-derived neurotrophic factor mRNA and protein in a human glioblastoma-astrocytoma cell line. Pharmachology. 2011; 87:5-10. IF=1.788
  65. Donohoe G, Rose E, Frodl T, Morris D, Spoletini I, Cherubini A, Bernardini S, Caltagirone C, Bossù P, Gill M, Corvin AP, Spalletta G. ZNF804A risk allele is associated with relatively intact grey matter volume in patients with schizophrenia. Neuroimage. 2011;54:2132-2137. IF=5.895
  66. Spoletini I, Piras F, Fagioli S, Rubino IA, Martinotti G, Siracusano A, Caltagirone C, Spalletta G. Suicidal attempts and increased right amygdala volume in schizophrenia. Schizophrenia Research. 2011;125:30-40. IF=4.748
  67. Piras F, Cherubini A, Caltagirone C, Spalletta G. Education mediates microstructural changes in bilateral hippocampi. Human Brain Mapping. 2011;32:282-289. IF=5.880
  68. Orfei MD, Varsi AE, Blundo C, Celia E, Casini A, Caltagirone C, Spalletta G. Anosognosia in Mild Cognitive Impairment and Mild Alzheimer’s Disease: Frequency and Neuropsychological Correlates. American Journal of Geriatric Psychiatry. 2010;18:1133-1140. IF=3.566
  69. Piras F, Caltagirone C, Spalletta G. Working memory performance and thalamus microstructure in healthy people. Neuroscience. 2010;171:496-505. IF=3.215
  70. Peran P, Cherubini A, Assogna F, Piras P, Quatrocchi C, Peppe A, Celsis P, Rascol O, Demonet JF, Stefani A, Pierantozzi M, Pontieri F, Caltagirone C, Spalletta G, Sabatini U. Magnetic resonance imaging markers of Parkinson’s disease nigrostriatal signature. Brain. 2010;133:3423-3433. IF=9.230
  71. 102. Assogna F, Pontieri FE, Peppe A, Cravello L, Pierantozzi M, Stefani A, Stanzione P, Pellicano C, Caltagirone C, Spalletta G. Intensity dependent facial emotion recognition and cognitive functions in Parkinson’s Disease. Journal of the International Neuropsychological Society. 2010;16:867-876. IF=2.919
  72. Spalletta G, Musicco M, Padovani P, Perri R, Canonico V, Trequattrini A, Pettenati C, Caltagirone C, Palmer K. Syndromes of Behavioral and Psychological Symptoms of Dementia in a large cohort of newly diagnosed, untreated Alzheimer disease patients. American Journal of Geriatric Psychiatry. 2010;18:1026-1035. IF=3.566
  73. Lambert JC, Sleegers K, Ingelsson M, Beechman G, Hiltunen M, Combarros O, Bullido MJ, Bettens K, Berr C, Pasquier F, Richard F, DeKosky ST, Hannequin D, Haines J, Fiévet N, Dartigues JF, Tzourio C, Engelborghs S, Arosio B, Coto E, De Deyn P, Del Zompo M, Mateo I, Epelbaum J, Franck A, Giedraitis V, Helisalmi S, Porcellini E, Forti P, Ferri R, Zelenika D, Lathrop M, Scarpini E, Siciliano G, Solfrizzi V, Sorbi S, Spalletta G, Ravaglia G, Valdivieso F, Vepsäläinen D, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossù P, Hanon O, Piccardi P, Annoni G, Mann D, Marambaud P, Seripa D, Galimberti D, Lendon C, Lannfelt L, Licastro F, Campion D, Pericak-Vance MA, Soininen H, Van Broeckhoven C, Alpérovitch A, Kamboh MI, Amouyel P. The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer’s disease : a meta-analysis study. Journal of Alzheimer’s Disease. 2010;22:247-255. IF=4.261
  74. Iuliano L, Monticolo R, Straface G, Spoletini I, Gianni W, Caltagirone C, Bossu P, Spalletta G. Vitamin E and enzymatic/oxidative stress-driven oxysterols in amnestic Mild Cognitive Impairment subtypes and Alzheimer’s disease. Journal of Alzheimer’s Disease. 2010;21:1383-1392. IF=4.261
  75. Adriano F, Spoletini I, Caltagirone C, Spalletta G. Updated meta-analyses reveal thalamus volume reduction in patients with first-episode and chronic schizophrenia. Schizophrenia Research. 2010;123:1-14. IF=4.374
  76. Spalletta G, Morris DW, Angelucci F, Rubino IA, Spoletini I, Bria P, Martinotti G, Siracusano A, Bonaviri G, Bernardini S, Caltagirone C, Bossù P, Donohoe G, Gill M, Corvin AP. BDNF Val66Met polymorphism is associated with aggressive behavior in schizophrenia. European Psychiatry. 2010;25:311-313. IF=3.365
  77. Caltagirone C, Spoletini I, Gianni W, Spalletta G. Inadequate pain relief and consequences in oncological elderly patients. Surgical Oncology. 2010;19:178-183. IF=2.886
  78. Spoletini I, Caltagirone C, Ceci M, Gianni W, Spalletta G. Management of pain in cancer patients with depression and cognitive deterioration. Surgical Oncology. 2010;19:160-166. IF=2.886
  79. Angelucci F, Ricci V, Martinotti G, Palladino I, Spalletta G, Caltagirone C, Bria P. Ecstasy (MDMA)-addicted subjects show increased serum levels of brain-derived neurotrophic factor, independently from arise of drug-induced psychotic symptoms. Addiction Biology. 2010;15:365-367. IF=4.152
  80. Robinson RG, Spalletta G. Poststroke Depression: A Review. Canadian Journal of Psychiatry. 2010;55:341-349. IF=2.497
  81. Orfei MD, Caltagirone C, Spalletta G. Ethical perspectives on relations between industry and neuropsychiatric medicine. International Review of Psychiatry. 2010;22:281-287. IF=1.781
  82. Madaio RA, Spalletta G, Cravello L, Ceci M, Repetto L, Naso G. Overcoming endocrine resistance in breast cancer. Current Cancer Drug Targets. 2010;10:519-528. IF=4.771
  83. Orfei MD, Spoletini I, Banfi G, Caltagirone C, Spalletta G. Neuropsychological correlates of cognitive insight in schizophrenia. Psychiatry Research. 2010;178:51-56. IF=2.803
  84. Cacciari C, Moraschi M, Di Paola M, Cherubini A, Orfei MD, Giove F, Maraviglia B, Caltagirone C, Spalletta G. White matter microstructure and apathy level in amnestic Mild Cognitive Impairment. Journal of Alzheimer’s Disease. 2010;20:501-507. IF=4.261
  85. Di Iulio F, Palmer K, Blundo C, Casini A, Gianni W, Caltagirone C, Spalletta G. Occurrence and patterns of neuropsychiatric symptoms and disorders in Mild Cognitive Impairment subtypes and Alzheimer’s disease. International Psychigeriatrics. 2010;22:629-640. IF=2.478
  86. Cerasa A, Cherubini A, Quattrone A, Gioia MC, Magariello A, Muglia M, Manna I, Assogna F, Caltagirone C, Spalletta G. Morphological correlates of MAOA VNTR polymorphism: new evidence from cortical thickness measurement. Behavioral Brain Research. 2010;211:118-124. IF=3.393
  87. 86. Spalletta G, Robinson RG. How should depression be diagnosed in patients with stroke? Acta Psychiatrica Scandinavica, Editorial. 2010;121:401-403. IF=3.795
  88. Di Paola M, Di Iulio F, Cherubini A, Blundo C, Casini AR, Sancesario G, Passafiume D, Caltagirone C, Spalletta G. When, where and how the corpus callosum changes in MCI and AD: a cross-sectional study. Neurology. 2010;74:1136-1142. IF=8.017
  89. Cerasa A, Cherubini A, Quattrone A, Gioia MC, Tarantino P, Annesi G, Assogna F, Caltagirone C, Spalletta G. Met158 variant of the COMT genotype is associated with thicker cortex in adult brain. Neuroscience. 2010;167:809-814. IF=3.215
  90. Spalletta G, Spoletini I, Cherubini A, Rubino IA, Siracusano A, Piras F, Caltagirone C, Marini A. Cortico-subcortical underpinnings of narrative processing impairment in schizophrenia. Psychiatry Research Neuroimaging. 2010;182:77-80. IF=2.131
  91. Spoletini I, Spalletta G. Priority evaluation Paper. White matter abnormalities in adolescent-onset and adult-onset schizophrenia: new directions in research. Future Neurology. 2010;5:195-198. IF=
  92. Cherubini A, Péran P, Spoletini I, Di Paola M, Di Iulio F, Hagberg GE, Sancesario G, Gianni W, Bossù P, Caltagirone C, Sabatini U, Spalletta G. Combined volumetry and DTI in subcortical structures of Mild Cognitive Impairment and Alzheimer’s Disease patients. Journal of Alzheimer’s Disease. 2010;19:1273-1282. IF=4.261
  93. Moraschi M, Hagberg GE, Di Paola M, Spalletta G, Maraviglia B, Giove F. Smoothing that does not blur: effects of the anisotropic approach for evaluating Diffusion Tensor Imaging data in the clinic. Journal of Magnetic Resonance Imaging. 2010;31:690-697. IF=
  94. Palmer K, Di Iulio F, Gianni W, Sancesario G, Caltagirone C, Spalletta G. Neuropsychiatric predictors of progression from amnestic Mild Cognitive Impairment to Alzheimer’s Disease: the role of depression and apathy. Journal of Alzheimer’s Disease. 2010;20:175-183. IF=4.261
  95. Di Paola M, Spalletta G, Caltagirone C. In vivo structural neuroanatomy of Corpus Callosum in Alzheimer’s Disease and Mild Cognitive Impairment using different MRI techniques: A review. Journal of Alzheimer’s Disease. 2010;20:67-95. IF=4.261
  96. Ciaramella A, Bizzoni F, Salani F, Vanni D, Spalletta G, Sanarico N, Vendetti S, Caltagirone C, Bossù P. Increased pro-inflammatory response by dendridic cells from patients with Alzheimer’s disease. Journal of Alzheimer’s Disease. 2010;19:559-572. IF=4.261
  97. Angelucci F, Spalletta G, di Iulio F, Ciaramella A, Salani F, Colantoni L, Varsi AE, Gianni W, Sancesario G, Caltagirone C, and Bossù P. Alzheimer’s disease (AD) and mild cognitive impairment (MCI) patients are characterized by increased BDNF serum levels. Current Alzheimer Research. 2010;7:15-20. IF=4.953
  98. Carlesimo GA, Cherubini A, Caltagirone C, Spalletta G. Hippocampal mean diffusivity and memory in healthy elderly individuals: a cross-sectional study. Neurology. 2010;74:194-200. IF=8.017
  99. Cherubini A, Spoletini I, Péran P, Luccichenti G, Di Paola M, Sancesario G, Gianni W, Giubilei F, Bossù P, Sabatini U, Caltagirone C, Spalletta G. A multimodal MRI investigation of the subventricular zone in Mild Cognitive Impairment and Alzheimer’s disease patients. Neuroscience Letters. 2010;469:214-218. IF=2.055
  100. Donohoe G, Frodl T, Morris D, Spoletini I, Canon D, Cherubini A, Caltagirone C, Bossù P, McDonald C, Gill M, Corvin AP, Spalletta G. Reduced occipital and pre-frontal brain volumes in Dysbindin associated schizophrenia. Neuropsychopharmacology. 2010;35:368-373. IF=6.685
  101. Di Paola M, Luders E, Di Iulio F, Cherubini A, Passafiume D, Thompson PM, Caltagirone C, Toga AW, Spalletta G. Callosal atrophy in Mild Cognitive Impairment and Alzheimer’s Disease: Different effects in different stages. Neuroimage. 2010;49:141-149. IF=5.932
  102. Scuteri A, Spalletta G, Cangelosi M, Gianni W, Assisi A, Brancati AM, Modestino A, Caltagirone C, Volpe M. Decreased nocturnal systolic blood pressure fall in older subjects with depression. Aging, Clinical and Experimental Research. 2009;21:292-297. IF=1.255
  103. Angelucci F, Ricci V, Spalletta G, Caltagirone C, Mathe AA, Bria P. Effects of psychostimulants on neurotrophins: implications for psychostimulant-induced neurotoxicity. International Review of Neurobiology. 2009;88:1-24. IF=4.017
  104. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fiévet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, the European Alzheimer’s Disease Initiative Investigators (Arosio B, Coto E, Del Zompo M, Deramecourt V, Epelbaum J, Forti P, Brice A, Ferri R, Scarpini E, Siciliano G, Solfrizzi V, Sorbi S, Spalletta G, Ravaglia G, Sahel J, Valdivieso F, Vepsäläinen S, Pilotto A), de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossù P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanché H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alpérovitch A, Lathrop M, Amouyel P. Genome-wide association study identifies genes identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nature Genetics. 2009;41:1094-1099. IF=34.284
  105. Musicco M, Palmer K, Salamone G, Lupo F, Perri R, Mosti S, Spalletta G, Di Iulio F, Pettenati C, Cravello L, Caltagirone C. Predictors of progression of cognitive decline in Alzheimer’s disease: the role of vascular and sociodemographic factors. Journal of Neurology. 2009;256:1288-1295. IF=2.903
  106. Bossù P, Salani F, Cacciari C, Picchetto L, Cao M, Bizzoni F, Rasura M, Caltagirone C, Robinson RG, Orzi F, Spalletta G. Disease Outcome, Alexithymia and Depression are Differently Associated with Serum IL-18 Levels in Acute Stroke. Current Neurovascular Research. 2009;6:163-170. IF=3.231
  107. Cherubini A, Péran P, Caltagirone C, Sabatini U, Spalletta G. Aging of subcortical nuclei: microstructural, mineralization and atrophy modifications measured in vivo using MRI. Neuroimage. 2009;48:29-36. IF=5.739
  108. Péran P, Cherubini A, Luccichenti G, Hagberg G, Démonet JF, Rascol O, Celsis P, Caltagirone C, Spalletta G, Sabatini U. Volume and iron content in basal ganglia and thalamus. Human Brain Mapping. 2009;30:2667-2675. IF=6.256
  109. Cravello L, Caltagirone C, Spalletta G. The SNRI venlafaxine improves emotional unawareness in patients with post-stroke depression. Human Psychopharmacology: Clinical and Experimental. 2009;24:331-336. IF=2.496
  110. Angelucci F, Bernardini S, Gravina P, Bellincampi L, Trequattrini A, Di Iulio F, Vanni D, Federici G, Caltagirone C, Bossù P, Spalletta G. Delusion Symptoms and Response to Antipsychotic Treatment are Associated with the 5-HT2A (102T/C) Receptor Polymorphism in Alzheimer’s Disease: A 3-Year Follow-up Longitudinal Study. Journal of Alzheimer’s Disease. 2009;17:203-211. IF=3.832
  111. Cherubini A, Péran P, Hagberg GE, Varsi AE, Luccichenti G, Caltagirone C, Sabatini U, Spalletta G. Characterization of white matter fiber bundles with T2* Relaxometry and Diffusion Tensor Imaging. Magnetic Resonance in Medicine. 2009;61:1066-1072. IF=3.225
  112. Spoletini I, Cherubini A, Di Paola M, Banfi G, Rüsch N, Martinotti G, Bria P, Rubino IA, Siracusano A, Caltagirone C, Spalletta G. Reduced fronto-temporal connectivity is associated with frontal gray matter density reduction and neuropsychological deficit in schizophrenia. Schizophrenia Research. 2009;108:57-68. IF=4.458
  113. Orfei MD, Caltagirone C, Spalletta G. The evaluation of anosognosia in stroke patients. Cerebrovascular Diseases. 2009;27:280-289. IF=3.535
  114. Ciaramella A, Sanarico N, Bizzoni F, Moro ML, Salani F, Scapigliati G, Spalletta G, Caltagirone C, Bossù P. Amyloid b peptide promotes differentiation of pro-inflammatory human myeloid dendritic cells. Neurobiology of Aging. 2009;30:210-221. IF=5.937
  115. Spalletta G, Tomaiuolo F, Di Paola M, Trequattrini A, Bria P, Macaluso E, Frackowiak RSJ, Caltagirone C. The neuroanatomy of verbal working memory in schizophrenia: a voxel-based morphometry study. Clinical Schizophrenia and Related Psychoses. 2008;2:79-87. IF=not assigned
  116. Rüsch N, Spoletini I, Wilke M, Martinotti G, Bria P, Trequattrini A, Bonaviri G, Caltagirone C, Spalletta G. Inferior frontal white matter volume in patients with schizophrenia and a history of suicide attempts. Psychiatry Research Neuroimaging. 2008;164:206-214. IF=2.638
  117. Robinson RG, Spalletta G, Jorge R, Bassi A, Colivicchi F, Ripa A, Caltagirone C. Decreased heart rate variability is associated with poststroke depression. American Journal of Geriatric Psychiatry. 2008;16:867-873. IF=4.022
  118. Cologno D, Buzzi MG, Cicinelli P, Caltagirone C, Spalletta G. Symtomatic cluster-Like headache triggered by forehead lipoma: a case report and review of the literature. Neurological Sciences. 2008;29:331-335. IF=1.435
  119. Donohoe G, Spoletini I, McGlade N, Behan C, Hayden J, O’Donoghue T, Peel R, Haq F, Spalletta G, Gill M, Corvin A, O’Callaghan E. Are relational style and neuropsychological performance predictors of social attributions in chronic schizophrenia? Psychiatry Research. 2008;161:19-27. IF=2.666
  120. Angelucci F, Ricci V, Spalletta G, Pomponi M, Tonioni F, Caltagirone C, Bria P. Reduced serum concentrations of nerve growth factor, but not brain-derived neurotrophic factor, in chronic cannabis abusers. European Neuropsychopharmacology. 2008;18:882-887. IF=3.661
  121. Marini A, Spoletini I, Rubino IA, Ciuffa M, Bria P, Martinetti G, Banfi G, Boccascino R, Strom P, Siracusano A, Caltagirone C, Spalletta G. The Language of Schizophrenia: An Analysis of Micro and Macrolinguistic Abilities and their Neuropsychological Correlates. Schizophrenia Research. 2008;105:144-155. IF=4.174
  122. Assogna F, Pontieri FE, Caltagirone C, Spalletta G. The recognition of facial emotion expressions in Parkinson’s disease. European Neuropsychopharmacology. 2008;18:835-348. IF=3.661
  123. Spoletini I, Marra C, Di Iulio F, Gianni W, Sancesario G, Giubilei F, Trequattrini A, Bria P, Caltagirone C, Spalletta G. Facial emotion recognition deficit in amnestic Mild Cognitive Impairment and Alzheimer Disease. American Journal of Geriatric Psychiatry. 2008;16:389-398. IF=4.022
  124. Spoletini I, Gianni W, Repetto L, Bria P, Caltagirone C, Bossù P, Spalletta G. Depression and cancer: an unexplored and unresolved emergent issue in elderly patients. Critical Reviews in Oncology and Hematology. 2008;65:143-155. IF=4.589
  125. Orfei MD, Robinson RG, Bria P, Caltagirone C, Spalletta G. Unawareness of illness in neuropsychiatric disorders: phenomenological certainty versus etiopathogenetic vagueness? The Neuroscientist. 2008;14:203-222. IF=5.896
  126. Bossù P, Ciaramella A, Salani F, Bizzoni F, Varsi E, Di Iulio F, Giubilei F, Gianni W, Trequattrini A, Moro ML, Caltagirone C, Spalletta G. Interleukin-18 produced by peripheral blood cells is increased in Alzheimer’s disease and correlates with cognitive impairment. Brain, Behaviour, and Immunity. 2008;22:487-592. IF=4.909
  127. Spalletta G, Bernardini S, Bellincampi L, Federici G, Trequattrini A, Ciappi F, Bria P, Caltagirone C, Bossù P. Glutathione S-Transferase P1 and T1 gene polymorphisms predict the longitudinal course and the age at onset of Alzheimer disease. American Journal of Geriatric Psychiatry. 2007;15:879-887. IF=3.498
  128. Spalletta G, Serra L, Fadda L, Ripa A, Bria P, Caltagirone C. Unawareness of motor and emotional impairment in right hemispheric stroke. International Journal of Geriatric Psychiatry. 2007;22:1241-1246. IF=2.197
  129. Orfei MD, Robinson RG, Prigatano GP, Starkstein S, Rusch N, Bria P, Caltagirone C, Spalletta G. Anosognosia for hemiplegia after stroke is a multifaceted phenomenon: a systematic review of the literature. Brain. 2007;130:3075-3090. IF=8.568
  130. Bossù P, Ciaramella A, Moro ML, Bellincampi L, Bernardini S, Federici G, Trequattrini A, Ciappi F, Macciardi F, Spoletini I, Di Iulio F, Caltagirone C, Spalletta G. Interleukin-18 gene polymorphisms are associated with risk and outcome of Alzheimer’s disease. Journal of Neurology Neurosurgery and Psychiatry. 2007;78:807-811. IF=3.857
  131. Rüsch N, Spoletini I, Wilke M, Bria P, Di Paola M, Di Iulio F, Martinotti G, Caltagirone C, Spalletta G. Prefrontal-thalamic-cerebellar gray matter networks and executive functioning in schizophrenia. Schizophrenia Research. 2007;93:79-89. IF=4.240
  132. De Girolamo G, Tempestini A, Cavrini G, Scocco P, Argentino P, Federici S, Putzu P, Zappia M, Morosini P, Cascavilla I, Azzarito C, Brancati G, Spalletta G, Calvaruso A, Lucidi F, Pasini A. Residential facilities for older people in Italy: a five-region survey. Aging Clinical and Experimental Research. 2007;19:132-138. IF=1.311
  133. Spalletta G, Caltagirone C. Why the use of benzodiazepines a few minutes before the imaging does not affect cerebral blood flow results in single photon emission computed studies. Biological Psychiatry. 2007;61:422. IF=8.456
  134. Spalletta G, Bria P, Caltagirone C. Temperament, character and psychopathology in subjects with different pattern of cannabis use. Psychopathology. 2007;40:29-34. IF=1.441
  135. Spalletta G, Bossù P, Ciaramella A, Bria P, Caltagirone C, Robinson RG. The etiology of poststroke depression: a review of the literature and a new hypothesis involving inflammatory cytokines. Molecular Psychiatry. 2006;11:984-991. IF=11.804
  136. Spoletini I, Caltagirone C, Bria P, Spalletta G. Apolipoprotein E e4 allelic variant, cognitive decline and psychosis in Alzheimer disease: a review of the literature and suggestions for upcoming studies. European Journal of Psychiatry. 2006;20:74-87. IF=Unaivailable
  137. Spalletta G, Ripa A, Bria P Caltagirone C, Robinson RG. Response of emotional unawareness following stroke to antidepressant treatment. American Journal of Geriatric Psychiatry. 2006;14:220-227. IF=2.894
  138. Macellari V, Giacomozzi C, Fadda A, Benvenuti F, Giampaoli S, Spalletta G, Cappozzo A, Stanhope SJ, Weinrich M, Stuart ME, Macko R. Obtaining optimal functional recovery and efficient managed care for the chronic stroke population. Rapporti ISTISAN. 2006;06:189-195.
  139. Spalletta G, Caltagirone C, di Michele F. Cortisol/DHEA ratios in schizophrenia – Reply to letter to the editor. Journal of Psychiatric Research. 2006;40:185. IF=3.7
  140. Spalletta G, Bernardini S, Bellincampi L, Federici G, Trequattrini A, Caltagirone C. Delusion symptoms are associated with ApoE e4 allelic variant at the early stage of Alzheimer’s disease with late onset. European Journal of Neurology 2006;13:176-182. IF=2.437
  141. Spalletta G, Bria P, Caltagirone C. The sensitivity of somatic symptoms in post-stroke depression. International Journal of Geriatric Psychiatry 2005;20:1103-1104. IF=2.16
  142. Bernardini S, Bellincampi L, Ballerini S, Federici G, Iori R, Trequattrini A, Ciappi F, Baldinetti F, Bossù P, Caltagirone C, Spalletta G. Glutathione S-transferase P1*C allelic variant increases susceptibility for late-onset Alzheimer’s disease: association study and relationship with ApoE e4 allele. Clinical Chemistry 2005;51:944-951. IF=7.717
  143. di Michele F, Caltagirone C, Bonaviri G, Romeo E, Spalletta G. Plasma dehydroepiandrosterone levels are strongly increased in schizophrenia. Journal of Psychiatric Research 2005;39:267-273. IF=3.301
  144. Spalletta G, Ripa A, Caltagirone C. Symptom Profile of DSM-IV Major and Minor Depressive Disorders in First-Ever Stroke Patients. American Journal of Geriatric Psychiatry 2005;13:108-115. IF=2.929
  145. Spalletta G, Romeo E, Bonaviri G, Bernardi G, Caltagirone C, di Michele F. Preliminary evidence for association between aggression, hostility and 5a-3a-tetrahydroprogesterone levels in schizophrenia. Journal of Psychiatry & Neuroscience 2005:30:49-52. IF=3.91
  146. Bossù P, Ciaramella A, Moro ML, Spalletta G, Caltagirone C. Alzheimer’s disease and immune activation: a translational perspective. Neuroscience Research Communication 2004;35:193-201. IF=0.386
  147. Sinibaldi L, De Luca L, Bellacchio E, Conti E, Pasini A, Paloscia C, Spalletta G, Caltagirone C, Pizzuti A, Dallapiccola B. Mutations of the Nogo-66 Receptor (RTN4R) Gene in Schizophrenia. Human Mutation 2004;24:534-535. IF=6.845
  148. Spalletta G, Caltagirone C. Global cognitive level and antidepressant efficacy in post-stroke depression. Psychopharmacology 2004;175:262-263. IF=3.146
  149. Spalletta G, Baldinetti F, Buccione I, Fadda L, Perri R, Scalmana S, Serra L, Caltagirone C. Cognition and behaviour are independent and heterogeneous dimensions in Alzheimer’s disease. Journal of Neurology 2004;251:688-695. IF=3.14
  150. Spalletta G, Caltagirone C. Sertraline treatment of post stroke major depression: an open study in patients with moderate to severe symptoms. Functional Neurology 2003;18:227-232. IF=0.375
  151. Spalletta G, Tomaiuolo F, Marino V, Bonaviri G, Trequattrini A, Caltagirone C. Schizophrenia as a brain misconnection syndrome: a white matter voxel-based morphometry study. Schizophrenia Research 2003;64:15-23. IF=4.072
  152. Spalletta G, Guida G, Caltagirone C. Is left stroke a risk factor for SSRI antidepressant treatment resistance? Journal of Neurology 2003;250:449-455. IF=2.778
  153. De Luca A, Conti E, Grifone N, Amati F, Spalletta G, Caltagirone C, Bonaviri G, Pasini A, Gennarelli M,  Stefano B, Berti L, Mittler G, Meisterernst M, Dallapiccola B, Novelli G. Association study between CAG trinucleotide repeats in the PCQAP gene (PC2 glutamine/Q-rich-associated protein) and schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2003;116B:32-35. IF=2.606
  154. Spalletta G, Guida G, De Angelis D, Caltagirone C. Predictors of cognitive level and depression severity are different in patients with left and right hemispheric stroke within the first year of illness. Journal of Neurology 2002;249:1541-1551. IF=3.345
  155. Spalletta G, Pasini A, Caltagirone C. Fluoxetine alone in treatment of first episode anxious depression: an open clinical trial. Journal of Clinical Psychopharmacology 2002;22:263-266. IF=4.205
  156. Spalletta G, Pasini A, Costa A, De Angelis D, Ramundo N, Paolucci S, Caltagirone C. Alexithymic features in stroke: effects of laterality and gender. Psychosomatic Medicine 2001;63:944-950. IF=2.815
  157. Spalletta G, Pasini A, Pau F, Guido G, Meneghini L, Caltagirone C. Prefrontal blood flow dysregulation in ADHD children without structural abnormalities. Journal of Neural Transmission 2001;108:1203-1216. IF=1.862
  158. Troisi A, Pasini A, Spalletta G. Season of birth, gender, and negative symptoms in schizophrenia. European Psychiatry 2001;16:342-348. IF=1.072
  159. De Luca A, Pasini A, Amati F, Botta A, Spalletta G, Alimenti S, Caccamo F, Conti E, Trakalo J, Macciardi F, Dallapiccola B, Novelli G. Association study of a promoter polymorphism of UFD1L gene with schizophrenia. American Journal of Medical Genetics 2001;105:529-533. IF=2.378
  160. Spalletta G, Troisi A, Alimenti S, Di Michele F, Pau F, Pasini A, Caltagirone C. Reduced prefrontal cognitive activation associated with aggression in schizophrenia. Schizophrenia Research 2001;50:135-136. IF=3.567
  161. Spalletta G, De Angelis D, Caltagirone C. Post-stroke depression and emotional incontinence. Neurology 2000;55:1760-1761. IF=4.781
  162. Strohle A, Pasini A, Romeo E, Hermann B, Spalletta G, di Michele F, Holsboer F, Rupprecht R. Fluoxetine decreases concentrations of THDOC in major depression. Journal of Psychiatric Research 2000;34:183-186. IF=2.33
  163. Strohle A, Romeo E, Hermann B, Pasini A, Spalletta G, di Michele F, Holsboer F, Rupprecht R. Concentrations of 3alpha-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biological Psychiatry 1999;45:274-277. IF=3.319
  164. Rupprecht R, Strohle A, Hermann B, di Michele F, Spalletta G, Pasini A, Holsboer F, Romeo E. Neuroactive steroid concentrations following metyrapone administration in depressed patients and healthy volunteers. Biological Psychiatry 1998;44:912-914. IF=2.405
  165. Romeo E, Strohle A, Spalletta G, di Michele F, Hermann B, Holsboer F, Pasini A, Rupprecht R. Effects of antidepressant treatment on neuroactive steroids in major depression. American Journal of Psychiatry 1998;155:910-913. IF=5.939
  166. Troisi A, Pasini A, Saracco M, Spalletta G.: Psychiatric symptoms in male cannabis users not using other illicit drugs. Addiction 1998;93:487-492. IF=1.62
  167. Troisi A, Spalletta G, Pasini A. Nonverbal behaviour deficits in schizophrenia: an ethological study of drug-free patients. Acta Psychiatrica Scandinavica 1998;97:109-115. IF=1.554
  168. Spalletta G, Pasini A, De Angelis F, Troisi A. Patients with deficit, nondeficit, and negative symptom schizophrenia: do they differ during episodes of acute psychotic decompensation? Schizophrenia Research 1997;24:341-348. IF=2.737
  169. Troisi A, Pasini A, De Angelis F, Spalletta G. Paranoid/belligerence and neuroleptic dosage in newly admitted schizophrenic patients. Journal of Clinical Psychopharmacology 1997;17:84-87. IF=5.094
  170. Spalletta G, Troisi A, Saracco M, Ciani N, Pasini A. Symptom profile, Axis II comorbidity, and suicidal behaviour in young males with DSM-III-R depresive illnesses. Journal of Affective Disorders 1996;39:141-148. IF=2.062
  171. Romeo E, Brancati A, De Lorenzo A, Fucci P, Furnari C, Pompili E, Sasso L, Spalletta G, Troisi A, Pasini A. Marked decrease of plasma neuroactive steroids during alcohol withdrawal. Clinical Neuropharmacology 1996;19:366-369. IF=1.251
  172. Spalletta G, Troisi A, Pasini A. Alexithymia in male cannabis users: the role of comorbid depressive disorders. Depression 1995/96;3:246-249. IF=1.652

Book Chapter:

  1. Spalletta G, Assogna F, Caltagirone C, Leentjens AFG. Anhedonia in Parkinson’s Disease and other movement disorders. In: Risner MS, Ed. Anhedonia: a comprehensive handbook. Volume II: neuropsychiatric and physical disorders. Springer. 2014.
  2. Robinson RG, Spalletta G. Stroke. In: Nemeroff CB, Schlapfer J, Eds. Neurobiology of Psychiatric Disorders. Handbook of clinical neurology collection. Elsevier. 2014.
  3. Orfei MD, Caltagirone C, Spalletta G. The Behavioral Measurement of Anosognosia as a Multifaceted Phenomenon. In: Prigatano GP, Ed. The Study of Anosognosia. Oxford University Press. 2010; 429-452.
  4. Angelucci F, Caltagirone C, Spalletta G, Bossù P. Nerve Growth Factor and Alzheimer’s Disease: Where Do We Stand Today and Where Should We Go? In: MacIntire GK, Ed. Nerve Growth Factor: New Research. Hauppauge, NY. Nova Science Publishers. 2008;
  5. Spalletta G, Caltagirone C. Depression and other neuropsychiatric complications. In: Stein J, Harvey RL, Macko RF, Winstein CJ, Zorowitz RD, Eds. Stroke Recovery and Rehabilitation. New York, NY. Demos Medical Publishing. 2009;453-467.
  6. di Michele F, Caltagirone C, Spalletta G. Neurosteroid Perturbation and Neuropsychiatric Symptoms in Schizophrenia: from the Mechanisms to the Treatment. In: Ritsner MS, Weizman A, Eds. Neuroactive Steroids in Brain Function, Behavior and Neuropsychiatric Disorders: Novel Strategies for Research and Treatment. Springer. 2008;325-336.
  7. Romeo E, Curatolo P, di Michele F, Spalletta G, Pompili E, Furnari C, Fucci P, Pasini A. Neurosteroid alterations in mood disorders associated with alcohol withdrawal. In: Genazzani AR, Petraglia F, Purdy RH, Eds. The Brain: Source and target for sex steroid hormones. New York, NY The Parthenon Publishing Group. 1996;113-119.

 

 

Last Updated on 18/04/2017

CategoryDocenti